Browse

S-Space

Browsing by Author Kim, Sung-Bae

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 36 of 36

Issue Date Title / Author(s) / CitationFileAltmetrics
2005-08
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor
DOI
2007-05
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
DOI
2008-03
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
DOI
2009-04
Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)

Lee, Sang Gyu; Jee, Young Geon; Chung, Hyun Chul; Kim, Sung-Bae; Ro, Jungsil; Im, Young-Hyuck; Im, Seock-Ah; Seo, Jae Hong

Breast Cancer Research and Treatment, Vol.114 No.3, pp.589-595

DOI
2011-01
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)
DOI
2012-01
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
DOI
2012-04
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01
DOI
2013-05
Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02
DOI
2014-08
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial
DOI
2014-12
Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer
view fileDOI
2014-12
Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling
view file
2015-07
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)
DOI
2015-08
Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
DOI
2015-10
A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer
DOI
2016-04
Circulating plasma biomarkers for TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer
DOI
2016-10
Prognostic value of axillary nodal ratio after neoadjuvant chemotherapy of doxorubicin/cyclophosphamide followed by docetaxel in breast cancer: A multicenter retrospective cohort study
DOI
2016-12
Clonal evolutionary analysis during HER2 blockade in HER2-positive inflammatory breast cancer: A phase II open-label clinical trial of afatinib plus /- vinorelbine
DOI
2017-04
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
DOI
2017-10
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
DOI
2017-11
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
DOI
2017-12
Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline
DOI
2018-11
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
DOI
2018-12
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
DOI
2019-01
Randomized Open Labe Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
DOI
2019-03
Correction to: ECM1 regulates cell proliferation and trastuzumab resistance through activation of EGF-signaling
view fileDOI
2019-04
Metropolitan Governance Matters: The Low Economic Performance of Metropolitan Cities in South Korea

Kim, Sung-Bae

Korean Journal of Policy Studies, Vol.34 No.1, pp. 43-72

view file
2019-05
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
view fileDOI
2019-05
Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: Results from the phase III, randomized PALOMA-2 study
DOI
2019-12
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial
DOI
2019-12
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
DOI
2020-02
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
DOI
2020-04
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
DOI
2020-06
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): A randomised, open-label, phase 2 trial
DOI
2020-10
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
DOI
2022-01
Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
DOI
2022-07
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
1

Seoul National University Library, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea TEL: 02-880-5567 Email: s-space@snu.ac.kr youtube

RSS 1.0 RSS 2.0 Atom

Hello

Browse

News About S-Space Seoul National University Library LOGIN